Chadwick Christine, MD


Dr. Chadwick Christine, a neurologist, is a specialist in the diagnosis and treatment of Parkinson's disease and other movement disorders. He is a graduate of Cornell University where he earned a bachelor of arts degree in physics and English and a medical degree. Christine completed a residency in neurology and postdoctoral fellowship at UCSF, focusing on the research of synaptic plasticity. He is a member of the Movement Disorders Clinic and a professor of neurology in the UCSF School of Medicine.


Parkinson's Disease and Movement Disorders Clinic
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2273
Fax: (415) 353-2898

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification


More about Chadwick Christine


Cornell University School of Medicine 1991


UCSF Medical Center, Neurology 1995


UCSF Medical Center, Synaptic plasticity 1999

Selected Research and Publications

  1. Fernández-Fournier M, Perry DC, Tartaglia MC, de May M, Boxer A, Coppola G, Christine CW, Huang EJ, Seeley WW, Miller BL, DeArmond SJ, Grinberg LT, Geschwind MD. Precipitous Deterioration of Motor Function, Cognition, and Behavior. JAMA Neurol. 2017 May 01; 74(5):591-596.
  2. Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
  3. Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord. 2016 Dec; 33:127-133.
  4. Goudreau JL, Pérez A, Aminoff MJ, Boyd JT, Burau KD, Christine CW, Leehey M, Morgan JC. Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America. J Neurol Sci. 2016 Jul 15; 366:74-81.
  5. Bega D, Luo S, Fernandez H, Chou K, Aminoff M, Parashos S, Walker H, Russell DS, Christine CW, Dhall R, Singer C, Bodis-Wollner I, Hamill R, Truong D, Mari Z, Glazmann S, Huang M, Houston E, Simuni T. Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. Mov Disord Clin Pract. 2015 Dec; 2(4):371-378.
  6. Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
  7. Fang JY, Pérez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I, Zweig RM, Goudreau JL. Parkinson's disease severity and use of dopaminergic medications. Parkinsonism Relat Disord. 2015 Mar; 21(3):297-9.
  8. Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O. No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. PLoS One. 2014; 9(12):e112287.
  9. Moonen AJ, Wijers A, Leentjens AF, Christine CW, Factor SA, Juncos J, Lyness JM, Marsh L, Panisset M, Pfeiffer R, Rottenberg D, Serrano Ramos C, Shulman L, Singer C, Slevin J, McDonald W, Auinger P, Richard IH. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. Parkinsonism Relat Disord. 2014 Jun; 20(6):644-6.
  10. Sidorsky TI, Christine CW, Epstein JH, Berger TG. Development of corticobasal syndrome in a patient with congenital erythropoietic porphyria. Parkinsonism Relat Disord. 2014 Mar; 20(3):349-50.
  11. Hess CP, Christine CW, Apple AC, Dillon WP, Aminoff MJ. Changes in the thalamus in atypical parkinsonism detected using shape analysis and diffusion tensor imaging. AJNR Am J Neuroradiol. 2014 May; 35(5):897-903.
  12. Fanara P, Wong PY, Husted KH, Liu S, Liu VM, Kohlstaedt LA, Riiff T, Protasio JC, Boban D, Killion S, Killian M, Epling L, Sinclair E, Peterson J, Price RW, Cabin DE, Nussbaum RL, Brühmann J, Brandt R, Christine CW, Aminoff MJ, Hellerstein MK. Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J Clin Invest. 2012 Sep; 122(9):3159-69.
  13. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012 Apr 17; 78(16):1229-36.
  14. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, Kaplan PL, Forsayeth J, Aminoff MJ, Bankiewicz KS. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther. 2012 Apr; 23(4):377-81.
  15. Christine CW, Marks WJ, Ostrem JL. Development of Parkinson's disease in patients with Narcolepsy. J Neural Transm (Vienna). 2012 Jun; 119(6):697-9.
  16. Hegde M, Glass GA, Dalmau J, Christine CW. A case of slow orthostatic tremor, responsive to intravenous immunoglobulin. Mov Disord. 2011 Jul; 26(8):1563-5.
  17. Chou KL, Zamudio J, Schmidt P, Price CC, Parashos SA, Bloem BR, Lyons KE, Christine CW, Pahwa R, Bodis-Wollner I, Oertel WH, Suchowersky O, Aminoff MJ, Malaty IA, Friedman JH, Okun MS. Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord. 2011 Jul; 17(6):440-5.
  18. Aminoff MJ, Christine CW, Friedman JH, Chou KL, Lyons KE, Pahwa R, Bloem BR, Parashos SA, Price CC, Malaty IA, Iansek R, Bodis-Wollner I, Suchowersky O, Oertel WH, Zamudio J, Oberdorf J, Schmidt P, Okun MS. Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord. 2011 Mar; 17(3):139-45.
  19. Valles F, Fiandaca MS, Eberling JL, Starr PA, Larson PS, Christine CW, Forsayeth J, Richardson RM, Su X, Aminoff MJ, Bankiewicz KS. Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery. 2010 Nov; 67(5):1377-85.
  20. Christine CW, Garwood ER, Schrock LE, Austin DE, McCulloch CE. Parkinsonism in patients with a history of amphetamine exposure. Mov Disord. 2010 Jan 30; 25(2):228-31.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.